Angel Lucio is the CEO of Tetraneuron, a Spanish biotech company focused on advancing gene therapy solutions for Alzheimer’s and other neurodegenerative diseases. They are currently leading the company’s growth phase and preparing for first-in-human trials of TET101. With over 17 years of leadership experience across Europe and Asia at major pharmaceutical companies, including Johnson & Johnson, Takeda, and Sanofi, Angel has a strong background in business development, M&A, and commercial operations. As a seed investor in early-stage biotech and health tech companies, they are dedicated to fostering innovative ventures that address critical medical needs.
This person is not in the org chart
This person is not in any teams
This person is not in any offices